// App-Quantinova.ai

1951 : A novel, potent and selective oral inhibitor of MEK1/2 for the treatment of solid tumors

Researchers

Presenter

  • Shu Lin

Principal Investigators

  • Xingdong Zhao

  • Zuwen Zhou

  • Haohan Tan

  • Ling Chen

  • Rui Tan

  • Weipeng Zhang

  • Lihua Jiang

  • Li Linghu

  • Jing Sun

  • Jiashu Zhou

  • Te Li

  • Yunlong Song

  • Weibo Wang

Medical Centers

  • Fochon Pharma, Inc, San Leandro, CA

  • Fochon Pharmaceuticals, Ltd, Chongqing, China

  • Shanghai Fosun Pharmaceutical Development Co., Ltd., Shanghai, China

Locations

  • United States

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Acute lymphoblastic leukemia

  • Non Small Cell Lung cancer

  • Acute myelocytic leukemia

  • Small cell lung cancer

  • Solid malignancies

  • Prostate cancer

  • Breast cancer

  • Colorectal Cancer

  • Lung Cancer

  • Melanoma

Biomarkers

  • Mitogen-activated protein kinase

  • Dual specificity mitogen-activated protein kinase kinase 1

  • B-Raf proto-oncogene, serine/threonine kinase

  • Breakpoint Cluster Region

  • Dual specificity mitogen-activated protein kinase kinase 2

  • Extracellular signal-regulated kinase

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • Trametinib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • I

Study Id's

  • NCT03932253

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved